

# ANUPAM RASAYAN INDIA LTD.

Date: June 12, 2021

To, <b>BSE Limited</b> , Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, India <b>SCRIP CODE: 543275</b>	To, Sr. General Manager National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex Bandra (East), Mumbai 400051, India SYMBOL: ANURAS
--	--

Dear Sir/Madam,

ARILSLDSTX20210612006

Subject: Investor Presentation

We enclose herewith a copy of the 'Investor Presentation' in respect of the Audited Financial Results (Consolidated and Standalone) for the fourth quarter and year ended on March 31, 2021

The Investor Presentation is also being hosted on the Company's website at www.anupamrasayan.com

We request you to kindly note the same and take into your records.

Thanking you,

Yours Faithfully, For, Anupam Rasayan India Limited

Juch Agarwa

Suchi Agarwal Company Secretary & Compliance Officer Membership No: A32822

**Encl: Investor presentation** 

Registered Office : 8110, GIDC Industrial Estate, Sachin, SURAT-394 230 Gujarat, India. 

 Tel.
 : +91-261-2398991-95

 Fax
 : +91-261-2398996

 E-mail
 : office@anupamrasayan.com

 Website
 : www.anupamrasayan.com

 CIN - L24231GJ2003PLC042988



BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 ©2020 – Anupam Rasayan India Limited, All Rights Reserved. ANUPAM RASAYAN INDIA LIMITED

# INVESTOR PRESENTATION

Q4FY21 & FY21 JUNE 2021



# **Tables of Contents** COMPANY Slide 03 FINANCIALS Slide 08 STRATEGIC PRIORITIES 5 Slide 16 OUR BUSINESS Slide 20 TEAM **J**5 Slide 28 INDUSTRY TRENDS 06 Slide 30

# COMPANY

About Anupam **Slide 04** 

Business Verticals Slide 05

Making a Mark Globally **Slide 06** 

Key Strength **Slide 07** 



# COMPANY About Anupam



### COMPANY AT A GLANCE



Established Custom Synthesis player with **37** years of track record



Specialises in **multi-step synthesis** undertaking complex chemical reactions to produce key specialty chemicals with focus on developing innovative manufacturing processes



Catering to globally relevant chemical & agrochemical companies, including **18 MNC** and cumulative 64 clients

GOI recognized three-star export house



Strong supply chain with backward **integrated facilities** 



~24,300 MT Manufacturing Capacity, spread over 6 manufacturing facilities Q

Strong technical capabilities in complex chemistries supported by an R&D team of **55** professionals



Incorporated in 1984, Company operates in two verticals, namely

- Life Science related Specialty Chemicals
- Other Specialty Chemicals
- 43 Complex products manufactured as of FY21



**1,350+** committed employees

**Strong and committed** Management Team


## COMPANY Business Verticals

#### **BUSINESS VERTICALS OVERVIEW Other Specialty** Life Science Related **Specialty Chemicals** Chemicals Agrochemicals **Specialty Pigments** (including Crop Protection) Manufacturing agro intermediates and agro active ingredients (insecticides, Specialty Dyes fungicides and herbicides) Personal Care Polymer Additives Manufacturing anti-bacterial and ultraviolet protection intermediates and ingredient Pharmaceuticals Developing intermediates and 'key starting materials' for APIs, material sciences and surface chemistry Contributes more than Contributes less than 90%\* 10%\* ۵۵۵ of revenues of revenues


Note: Financials, revenue from operations proportion rounded-off to zero decimal also \*as of FY21.

### HISTORICAL BUSINESS PERFORMANCE

#### Revenue from Life Science (In ₹ Mn)




#### Revenue from Other Specialty Chemicals (In ₹ Mn)



# Making a Mark Globally



### **REVENUE BY GEOGRAPHY**



Note: All percentages above have been rounded-off to zero decimal. \*as of FY21.

ANUPAM RASAYAN INDIA LIMITED | 6

#### COMPANY

# **Key Strength: Customer Stickiness**

### FEW OF OUR TOP GLOBAL CLIENTS

- Long-standing relationships, clients onboarded after significant gestation period
- Stringent customer audits, approvals & requirements adhered
- Dealing with top MNC's around the globe supplying niche molecules to them
- Expertise in executing complex chemistries & products
- Focused on cornering higher wallet-share with scalable clients
- Focused on becoming preferred partner for top clients, for all current as well as future product additions

### LONG TERM CONTRACTS

- Validity of the contract ranging between 2 to 5 years
- Long term contracts enhance visibility of operations and helps in planning CAPEX



## **REVENUE FROM TOP 10 CUSTOMER**





- Top 10 customers contribution to reduce significantly over the next three years
- Top 10 customers contribute 23 products
- For the key customers, company have long term contracts in the range of two to five years

# FINANCIALS

Quarterly Financial Highlights Slide 09

Financial Summary Slide 10

Highlights & Ratio Analysis **Slide 12** 



# FINANCIALS Quarterly Financial Highlights



Operating Revenue was <b>₹ 2,717 Mn</b> .; Y-o-Y growth of <b>73%</b>	EBITDA (Incl. Other Revenue) was <b>₹ 655 Mn</b> .; Y-o-Y growth of <b>60%</b>	PAT stood at <b>₹ 221 Mn.</b> , Y-o-Y growth of <b>113%</b>
PAT Margin grew by <b>179bps</b> stood at <b>8%</b> for Q4FY21	Repaid significant debt by utilizing the IPO proceeds	
TOTAL REVENUE (In ₹ Mn) 2,742 As compared to revenue of ₹ 1,653 Mn in Q4FY20	TOTAL REVENUE GROWTH (In %) 66%	TOTAL NO. OF PRODUCTS (In Nos) 43 (as of Q4FY21)
Note: All numbers above have been rounded-off to zero decimal.		ANUPAM RASAYAN INDIA LIMITED   9

# FINANCIALS Profit & Loss Summary



(All amounts are in ₹ Mn)	Q4FY20	Q4FY21	FY20	FY21
INCOME				
Revenue from Operations	1,571	2,717	5,289	8,109
Other Income	82	25	109	264
Total Revenue	1,653	2,742	5,398	8,373
Total Revenue Growth (%)		66%		55%
EXPENSES:				
Cost of Raw Materials Consumed	675	1,213	2,105	3,390
Gross Profit	895	1,504	3,183	4,719
Gross Margins (%)	57%	55%	60%	58%
Gross Profit growth (%)		68%		48%
Employee Benefits Expenses	59	120	211	324
Other Expenses	509	753	1625	2457
EBITDA (Incl. Other Revenue)	409	655	1456	2202
EBITDA Margins (%)	25%	24%	27%	26%
EBITDA Growth (%)		60%		51%
Finance Cost	131	189	453	685
Depreciation and Amortization	113	133	287	517
Profit Before Tax	165	332	717	1000
Tax (Including Deferred Tax)	61	110	185	297
Profit for the Year	104	221	532	703
PAT Margins (%)	6%	8%	10%	8%
PAT Growth (%)		113%		32%

Note: All numbers above have been rounded-off to zero decimal.

ANUPAM RASAYAN INDIA LIMITED | 10

# FINANCIALS Balance Sheet Summary



(All amounts are in ₹ Mn)	FY20	FY21
Shareholders' Funds	5,935	15,734
Non-Current Liabilities	6,335	4,001
Long-Term Borrowings	5,814	3,435
Other Long-Term Borrowings	520	566
Current Liabilities	4,373	3,245
Short-Term Borrowings	2,371	433
Trade Payables	1,302	1,996
Other Current Liabilities	700	815
Total Equity and Liabilities	16,643	22,980
Non-Current Assets	11,125	11,834
Net Fixed Asset	10,655	11,467
Financial Assets	34	33
Other Non-Current Assets	437	334
Current Assets	5,518	11,147
Inventories	2,970	4,922
Trade Receivables	1,295	2,055
Cash and Cash Equivalent	268	2,957
Other Current Assets	984	1,212
Total Assets	16,643	22,980


Note: All numbers above have been rounded-off to zero decimal

ANUPAM RASAYAN INDIA LIMITED | 11

## FINANCIALS Highlights & Ratio Analysis (1/2)


**REVENUE FROM OPERATIONS, EBITDA & EBITDA** 

MARGINS



# FIXED ASSETS & FIXED ASSET TURNOVER RATIO

### (In ₹ Mn & Times)



### NET-DEBT, EQUITY & NET DEBT TO EQUITY

#### (In ₹ Mn & Times)





### FINANCIALS Highlights & Ratio Analysis (2/2)

### **CAPITAL EMPLOYED & ROCE**

(In ₹ Mn and %)



# Profit After Tax (In ₹ Mn) 800 700 600


400

300

200

FY18





### Return on Equity will improve significantly as new capacity comes into play and also due to various cost reduction measures taken by the company.

٠

#### Note: ROCE is calculated using Average capital employed & ROE is calculated using Average equity All numbers above have been rounded-off to zero decimal.

## FINANCIALS IPO Fund Utilization & Impact Analysis

The net proceeds of the Issue was proposed to be utilized in the following manner:

- Prepayment of certain indebtedness availed by the Company of ₹ 5,637 Mn
- Enhance our visibility and our brand image among our existing and potential customers

As of FY21 we have repaid ₹ 4,705 Mn of our Total debt



Net worth stands at over ₹15,734 Mn with significantly reduced debt., providing further headroom for organic and in-organic

•

growth

- Repayment from IPO Proceeds reduces borrowings
- Further expansion of profitability & improved cash flows
- Significant Improvement in Credit Rating of the company from CRISL A- to CRISIL A

Note: All numbers above have been rounded-off to zero decimal except Net-Debt to Equity which is rounded-off to two decimal.

## FINANCIALS Managing Director's Message






# Mr. Anand S Desai

We built on the momentum that we had in FY 20 across all our markets and product segments in FY 21. This fiscal was a unique one in the history of the Company as we went public with strong support from our esteemed shareholders. This apart, our focus on working with marquee clients continued with our association with Adama and we ended the year with 64 clients. The overall visibility across markets and products translated to a 55% increase in revenue while our EBITDA also increased by almost 51% to close at ₹ 2,202 million. The outlook for the Company looks strong and we are confident on building on this growth trajectory as we move forward.

# STRATEGIC PRIORITIES

Key Strategic Priorities Slide 17

EHS at Anupam Rasayan **Slide 18** 



ANUPAM RASAYAN INDIA LIMITED | 17

## STRATEGIC PRIORITIES EHS at Anupam Rasayan





#### STRATEGIC PRIORITIES

# EHS at Anupam Rasayan<sub>(cont.)</sub>



# (F)

## SUSTAINABILITY

- Installation of Solar Power plant to reduce dependency
- Use of Natural gas-based steam
- Hot Oil Boilers
- Minimize Carbon footprint by reducing fossil fuel dependency



## CSR ACTIVITIES

- Sickle Cell Disease comprehensive care program
- To reduce Neonatal Mortality Rate (NMR), Infant Mortality Rate (IMR) and child malnutrition in six tribal blocks of Gujarat
- Upgradation of Physiotherapy Department of Dinbandhu Charitable Hospital Trust
- Environment conservation and protection of flora and fauna
- Skill Angel Cognitive Learning Program

AWARDS & RECOGNITION





# OUR BUSINESS

Evolution of Anupam **Slide 21** 

Strong Technical Capabilities
Slide 22

Anupam's Value Chain **Slide 24** 

Infrastructure **Slide 25** 




# OUR BUSINESS **Evolution of Anupam**



Company was for partnership firm Rasayan"		Started supplying chemicals to Syn		Awarded 'Green I Award' by Cornin Technology (for the year 2015	g Reactor	Commercialized U Jhagadia GIDC ar Sachin GIDC		<ul> <li>Started working with Adama</li> <li>Listed on BSE &amp; NSE in Mar. 2021</li> </ul>
1984		2010		2016		2019		2021
	2006 Started supply of Anti-Bacterial proc to a European cus		2014 Commercialized Uf Jhagadia GIDC	nit – 4 in	2017 Eter Started supplying chemicals to Sumi Chemical in Japan	tomo	2020 Received DSIR ( R&D centre in S Started working Limited	Sachin Unit – 6


# OUR BUSINESS Strong Technical Capabilities

®



# OUR BUSINESS Strong Technical Capabilities (Contd.)


### PROCESS TECHNOLOGIES DEPLOYED



### Flow Chemistry

Significant advantages of flow chemistry technology over traditional batch process :

- Reduced lead-time
- Material-efficient & cost benefits
- Reduce environmental impacts in the laboratory
- One of the leading Indian companies in manufacturing products using continuous & flow chemistry technology on a commercial scale.




### **Photo Chemistry**

Increasingly becoming an important tool in the search of new active compounds for specialty chemicals & pharmaceuticals; relatively new technology for specialty chemicals, leading to benefits such as:

- Shorter & simplified multistep synthesis of complex molecules
- Larger potential for automation
- Increased accessibility of a portfolio of novel compound families
- Required micro reactors unlike conventional photo chemical systems which require larger reactors

# OUR BUSINESS Anupam's Value Chain






### CUSTOMER RETENTION


- Acquiring customers is typically a 15-27 months process
- Customers are required to register manufacturer with regulatory bodies & hence suppliers are selected only after careful review. This builds in customer stickiness
- Additionally, to limit spread of sensitive & confidential information, only a limited number of suppliers are selected

# OUR BUSINESS World-class Infrastructure

**\*\*** 

- Manufacturing operations were commenced in 1984
- Highly automated multi-purpose facilities
- Equipped with glass-lined, titanium cladded and stainless-steel reactors enabling manufacture of diverse range of products
- Strategically located close to the ports
- In the last 3 years, the Company has undertaken a massive CAPEX to double the manufacturing capacity





## MANUFACTURING CAPACITY



Facility	Installed Capacity (MT)	Capacity Utilization (%)
Sachin Unit – 1	5,202	89%
Sachin Unit – 2	2,520	81%
Sachin Unit – 3	6,130	85%
Jhagadia Unit – 4	3,685	75%
Jhagadia Unit – 5	5,520	52%
Sachin Unit – 6	1,238	59%
Total	24,295	74%

Note: All numbers & percentages above have been rounded-off to zero decimal.

# OUR BUSINESS Production Facilities (1/2)

### INFRASTRUCTURE – UNIT IV PRODUCTION SITE (JHAGADIA)







### INFRASTRUCTURE – UNIT V PRODUCTION SITE (JHAGADIA)



ANUPAM RASAYAN INDIA LIMITED | 26



# OUR BUSINESS Production Facilities (2/2)



### INFRASTRUCTURE – UNIT III (SACHIN)







### NEW R&D CENTRE AND PILOT FACILITIES







# TEAM

Board of Directors Slide 29



# Board of Directors



DR. KIRAN C PATEL CHAIRMAN & NON-EXECUTIVE DIRECTOR

 Associated with the company for past 5 years and intends to stay committed with company for long term



MR. ANAND S DESAI MANAGING DIRECTOR

 Over 28 years of experience in chemicals industry associated with the Company since 1992 & was one of the first Directors of the Company



MS. MONA A DESAI VICE-CHAIRMAN & WHOLE-TIME DIRECTOR

 Over 18 years of experience in chemicals industry and associated with the Board since the incorporation of the Company



MR. MILAN THAKKAR NON-EXECUTIVE DIRECTOR

 Associated with the company for past 8 years and intends to stay committed with company for long term



MR. HETUL KRISHNAKANT MEHTA



DR. NAMRATA DHARMENDRA JARIWALA



MR. VIJAY KUMAR BATRA



MR. VINESH PRABHAKAR SADEKAR INDEPENDENT DIRECTOR

OTHER KEY MANAGERIAL PERSONNEL

**MR. AFZAL MALKANI** CHIEF FINANCIAL OFFICER DR. NILESHKUMAR NAIK TECHNICAL HEAD

DR. ANUJ THAKAR R&D (PROCESS DEVELOPMENT) HEAD AND UNIT II HEAD MR. RAVI DESAI SALES HEAD

MS. SUCHI AGARWAL COMPANY SECRETARY AND COMPLIANCE OFFICER

# INDUSTRY TRENDS

Indian Chemical Industry Slide 31

CRAMS Industry Overview Slide 32

Specialty Chemicals – Industry Overview **Slide 33** 

Agrochemicals & API – Industry Overview **Slide 34** 

# Indian Chemical Industry at a Glance






<b>USD 178 Bn</b> (FY20)	<b>6<sup>th</sup></b> Largest Chemical Producer of the world	<b>80,000+</b> Products
<b>USD 130/month</b> Labor cost (one of Lowest in world)	<b>100%</b> FDI under automatic rule (except for Hazardous Chemical)	Fast Growing verticals: <b>Petrochemical</b> , <b>Specialty Chemical</b> & <b>Agrochemical</b>
Specialty Chemical <b>~50%</b> of total chemical export	~ <b>5%</b> of Global Chemical Export	~2.5% of Global Chemical Sales is contributed by India

Note: Source PwC & FICCI 2021 Report.

# INDUSTRY TRENDS CRAMS Industry Overview




### GLOBAL CRAMS INDUSTRY OVERVIEW



#### **KEY DRIVERS & TRENDS FOR GLOBAL CRAMS**

- Pace of contract manufacturing has been increasing, with companies shifting their focus on core activities driven by outsourcing of production to low manufacturing cost destinations
- With the spread of COVID-19, global manufacturing base is expected to transition from China to other potential regions (such as, Indian sub-continent & South East Asia) driven by global strategy shift of reducing existing dependency on single country

### INDIAN CRAMS INDUSTRY OVERVIEW




#### **KEY DRIVERS & TRENDS FOR INDIAN CRAMS**

- Indian CRAMS market is expected to grow at 12% in the next 5 years, owing to strong growth from end-use demand. 'China plus one' strategy & shift in manufacturing operations from China provides opportunity for India to capture larger market share
- Products worth USD 4.2 bn are expected to go off-patent by the year 2020 2023, globally. This will present a great opportunity for contract manufacturers postpandemic

#### INDUSTRY TRENDS

# **Specialty Chemicals – Industry Overview**

GLOBAL SPECIALTY CHEMICALS INDUSTRY OVERVIEW



### **KEY DRIVERS & TRENDS FOR GLOBAL SPECIALTY CHEMICALS**

- Rapid industrialization in India and China is expected to drive demand for specialty chemicals
- Asia-Pacific region has a market share of 44%, owing to the large customer base, leading to high demand for specialty chemicals, increasing industrial production, and robust growth of the construction sector in the region

### INDIAN SPECIALTY CHEMICALS INDUSTRY OVERVIEW



#### **KEY DRIVERS & TRENDS FOR INDIAN SPECIALTY CHEMICALS**

- India offers low cost of labour, lower operating costs, competitive infrastructure, SEZs, incentives to boost domestic manufacturing, and business-friendly policies
- India accounts for approximately 1% to 2% of the global exportable specialty chemicals, indicating a large scope of improvement and widespread opportunity
- Gol's 'Make in India' campaign is also expected to act as a stimulus to the emergence of India as a manufacturing hub for the chemicals industry
- Other factors include India's low corporate tax rate, India's improving "Ease of Doing Business" ranking and India's low amount of external debt



#### INDUSTRY TRENDS

# **Agrochemicals & API – Industry Overview**



#### **KEY DRIVERS & TRENDS FOR AGROCHEMICALS**

- India has one of the lowest per capita consumption of crop protection chemicals per hectare there is significant amount of growth opportunity
- Government initiative to double farmer's income through various measures (budgetary provisions, increasing minimum support prices)
- Increasing food demand due to increasing population addressing food security is important



#### **KEY DRIVERS & TRENDS FOR API**

- Increased focus on new geographies in the global pharmaceutical industry, change to specialty segment and strong domestic demand in relation to the Indian API industry
- Indian API manufacturers making efforts to improve marketing ability by raising production yields, changing production processes & increasing international markets sales
- Setting-up of unique zones and bulk drug parks under PPP model (Gol funding 70% of project costs). PLI scheme for promotion of domestic production of key starting materials / direct intermediates & APIs is planned

®

## Safe Harbor Safe Harbor



Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations. Anupam Rasayan India Limited will not be responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances



# THANK YOU

# CONTACT US:

MR. AFZAL MALKANI (CFO) Anupam Rasayan India Ltd. Tel: +91 261 2398991 investors@anupamrasayan.com

**MR. NIKHIL MORYE** Christensen Investor Relations Tel: +91 22 4215 0210 nmorye@christensenir.com

### **CORPORATE OFFICE**

Anupam Rasayan India Ltd. India (HQ) 8110, Sachin G.I.D.C. Estate, Sachin, Surat – 394 230, Gujarat, India.